SCHEMBL2018377

SCHEMBL2018377

CNC(=O)C1CCNC1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 1/20 0.44
POLB P06746 2/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.40
KLK5 Q9Y337 1/20 0.39
CFTR P13569 1/20 0.39
ACACB O00763 1/20 0.39
GLA P06280 1/20 0.39
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 1/20 0.38
CCR2 P41597 2/20 0.38
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22015866 0.82 L3MBTL1 (0.44) L3MBTL1ALDH1A1POLBHTTHSD17B10
SCHEMBL16671757 0.81 ALDH1A1 (0.46) L3MBTL1ALDH1A1POLBHTTHSD17B10
Hydrochloric Acid SCHEMBL4094535 0.79 L3MBTL1 (0.54) L3MBTL1ALDH1A1POLBHTTHSD17B10
SCHEMBL12376717 0.79 ACACB (0.47) L3MBTL1ALDH1A1POLBHTTHSD17B10
SCHEMBL20520368 0.78 L3MBTL1 (0.42) L3MBTL1ALDH1A1POLBHTTHSD17B10
SCHEMBL11674331 0.77
SCHEMBL21662208 0.76 L3MBTL1 (0.41) L3MBTL1ALDH1A1POLBHTTHSD17B10
SCHEMBL43971 0.76 L3MBTL1 (0.41) L3MBTL1ALDH1A1POLBHTTHSD17B10
SCHEMBL12409535 0.74 ACACB (0.55) L3MBTL1ALDH1A1HTTHSD17B10ACACB
SCHEMBL24108598 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093623-B2 Cyclic amides as MetAP-2 inhibitors MERCK PATENT GMBH (DE) 2018-10-09 US claimed
US-8871208-B2 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof ABBVIE INC. (US) 2014-10-28 US disclosed
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-06-30 US disclosed
WO-2011068927-A2 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC L3MBTL1 3393/4885ALDH1A1 1635/4885POLB 3275/4885
US-10093623-B2 Cyclic amides as MetAP-2 inhibitors METAP2, METAP1, LNPEP L3MBTL1 1386/4885ALDH1A1 3706/4885POLB 1010/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 L3MBTL1 3364/4885ALDH1A1 1929/4885POLB 1523/4885
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF HSD11B1, HSD17B1, HSD11B2 L3MBTL1 3678/4885ALDH1A1 58/4885POLB 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.